drugset / Trial / NCT00590070

THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction

NCT00590070

Phase 2/3 Completed 240 enrolled Catholic University of the Sacred Heart
RandomizedParallel-groupTriple-blindTreatment

Summary

The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases. This event is associated with a worse prognosis at follow up and an unfavourable left ventricular remodelling . Two main pathogenetic mechanisms cause no-reflow: distal embolization and ischemia-reperfusion injury. Due to the multifactorial pathogenesis of no-reflow during acute MI a combined mechanic and pharmacologic approach is believed to offer a better solution for achieving optimal microvascular reperfusion. Thus, in this randomized study we will assess the effect of nitroprusside or adenosine in adjunct to current best therapy (thrombus aspiration and IIb-IIIa antagonists) for ST elevation MI using ST segment resolution on standard 12 leads ECG as primary endpoint of myocardial reperfusion.

Timeline

Start
2008-01
Primary completion
2011-06
Completion
2011-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adenosine Small molecule 2 mg Intravenous
Comparator nitroprusside Other / unclassified 100 ug Intravenous

Indications